Akkermansia muciniphila primes lung-resident antiviral immunity via the gut–lung axis during SARS-CoV-2 infection
These findings position <i>A. muciniphila</i> as both a biomarker of COVID-19-related gut dysbiosis and a potent live biotherapeutic candidate for respiratory infections. Its ability to enhance mucosal immune responses through gut-lung axis modulation highlights its promise in prophylactic strategies against viral respiratory diseases, including SARS-CoV-2.
Authors
- Jun-Soo Do
- Gi-Cheon Kim (ORCID: https://orcid.org/0000-0003-4326-0454)
- Emmanuel Hitayezu (ORCID: https://orcid.org/0000-0002-3822-3619)
- Kwang Hyun (ORCID: https://orcid.org/0000-0003-3001-3067)
- Jiseon Kim (ORCID: https://orcid.org/0000-0002-5367-2148)
- Intan Rizki Mauliasari
- Donghun Jeon (ORCID: https://orcid.org/0000-0002-9161-6198)
- Su-bin Lee
- Jeong Jin Kim (ORCID: https://orcid.org/0009-0009-6987-1502)
- S W KIm
- Kwon Hj
- Ki Taek Nam
- Naeok Koo
- Jun-Young Seo
- Je Kyung Seong
Institutions
- Gangneung–Wonju National University (KR)
- Seoul National University (KR)
- Yonsei University (KR)
- AST Products (United States) (US)
- Creative Research (GB)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-27
- DOI
- https://doi.org/10.3389/fimmu.2026.1762843
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00